EXOZYMES INC

Company Overview

eXoZymes, Inc. is a pre‑revenue, development‑stage synthetic biology company that designs AI‑aided, engineered enzymes ("exozymes") to run multi‑enzyme, cell‑free biomanufacturing cascades. Near‑term targets are low‑volume, high‑value natural products (initially nutraceuticals with potential to become APIs) and select strategic programs such as a DOE‑funded isobutanol project for sustainable aviation fuel. The company is research‑intensive (~31 FTEs at a 10,000 sq. ft. Monrovia, CA facility), has a patent portfolio plus an exclusive UCLA license with milestone/royalty obligations, and is funded mainly by grants (~$13.6M historically) and recent IPO proceeds (net ~ $15.2M) used to support scale‑up and staffing.

Executive Compensation Practices

Since the November 2024 IPO, compensation expense has risen materially as the company added administrative hires, increased R&D headcount, accrued bonuses and began paying new directors’ fees and D&O insurance—consistent with the MDA’s disclosure that G&A and R&D payrolls climbed sharply. Given the firm’s pre‑revenue status and cash sensitivity (cash fell from ~$9.7M at year‑end 2024 to ~$7.0M by June 30, 2025), management is likely to emphasize equity‑based pay (options/RSUs) and milestone‑linked incentives to conserve cash and align executives with long‑term commercialization and licensing outcomes. Practical compensation drivers at eXoZymes will therefore be R&D progress, successful scale‑up to commercial yields, grant and partner funding milestones, and achievement of UCLA license milestones (which trigger potential royalty/sublicense revenue and may also trigger managerial bonuses or vesting events).

Insider Trading Considerations

As a recently public, small‑float biotech with meaningful event risk, insider trades can carry outsized signaling value—sales or buys by officers/directors may reflect views on runway (cash fell ~28% in H1 2025) or prospects for imminent grant, partner or license milestones. Watch for lock‑up expirations, Section 16 reporting (Form 3/4/5), and potential 10b5‑1 plans that govern the timing of trades; short‑swing profit exposure under Section 16(b) also applies given stock‑based compensation. Material catalysts that make trades especially informative include grant awards/receipts, partner deals or spin‑out announcements, successful pilot scale‑up, and regulatory/standards outcomes (FDA for therapeutics, ASTM/EPA for biofuels); low liquidity means insider sales can move the market and should be evaluated in the context of disclosed cash runway and milestone timing.